Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SL-145
- Development stage
- Preclinical
- Lead developer
- Korea University
01
Overview
SL-145: sourced facts only. name: "In this study, we sought to investigate whether a novel C-terminal HSP90 inhibitor SL-145 could resolve metastasis in TNBC through inhibition of cancer stem-like properties." [DOI:10.1158/1538-7445.am2022-3712]; target: "In this study, we sought to investigate whether a novel C-terminal HSP90 inhibitor SL-145 could resolve metastasis in TNBC through inhibition of cancer stem-like properties." [DOI:10.1158/1538-7445.am2022-3712]; developer: "1Korea University College of Medicine, Korea University, Seoul, Republic of Korea." [DOI:10.1158/1538-7445.am2022-3712]; stage: "An orthotopic allograft model with 4T1 mammospheres was used to examine the effect of SL-145 on tumor growth and metastasis in vivo." [DOI:10.1158/1538-7445.am2022-3712]
02
Targets
HSP90AA1 (Heat shock protein HSP90-alpha)
Beyond the preview
Go deeper on SL-145.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SL-145.